Department of Orthopedic Surgery, University of Kansas Medical Center, Kansas City, Kansas.
Foot Ankle Spec. 2022 Jun;15(3):201-208. doi: 10.1177/1938640020950181. Epub 2020 Aug 24.
Surgical management of end-stage ankle arthritis consists of either ankle arthrodesis (AA) or total ankle replacement (TAR). The purpose of this study was to evaluate utilization trends in TAR and AA and compare cost and complications.
Medicare patients with the diagnosis of ankle arthritis were reviewed. Patients undergoing surgical intervention were split into AA and TAR groups, which were evaluated for trends as well as postoperative complications, revision rates, and procedure cost.
A total of 673 789 patients were identified with ankle arthritis. A total of 19 120 patients underwent AA and 9059 underwent TAR. While rates of AA remained relatively constant, even decreasing, with 2080 performed in 2005 and 1823 performed in 2014, TAR rates nearly quadrupled. Average cost associated with TAR was $12559.12 compared with $6962.99 for AA ( < .001). Overall complication rates were 24.9% in the AA group with a 16.5% revision rate compared with 15.1% and 11.0%, respectively, in the TAR group ( < .001). Patients younger than 65 years had both higher complication and revision rates.
TAR has become an increasingly popular option for the management of end-stage ankle arthritis. In our study, TAR demonstrated both lower revision and complication rates than AA. However, TAR represents a more expensive treatment option.
Level III: Retrospective comparative study.
终末期踝关节关节炎的手术治疗包括踝关节融合术(AA)或全踝关节置换术(TAR)。本研究的目的是评估 TAR 和 AA 的使用趋势,并比较成本和并发症。
对患有踝关节关节炎的医疗保险患者进行了回顾性研究。将接受手术干预的患者分为 AA 和 TAR 两组,评估其趋势以及术后并发症、翻修率和手术成本。
共确定了 673789 例踝关节关节炎患者。共 19120 例患者接受 AA 治疗,9059 例患者接受 TAR 治疗。尽管 AA 的比例保持相对稳定,甚至有所下降,2005 年进行了 2080 例,2014 年进行了 1823 例,但 TAR 的比例几乎翻了两番。TAR 相关的平均成本为 12559.12 美元,而 AA 为 6962.99 美元( <.001)。AA 组的总体并发症发生率为 24.9%,翻修率为 16.5%,而 TAR 组分别为 15.1%和 11.0%( <.001)。年龄小于 65 岁的患者并发症和翻修率均较高。
TAR 已成为治疗终末期踝关节关节炎的一种越来越受欢迎的选择。在我们的研究中,TAR 显示出比 AA 更低的翻修和并发症发生率。然而,TAR 代表了一种更昂贵的治疗选择。
三级:回顾性比较研究。